Fisher & Paykel Healthcare Corporation LtdShs Aktie
| 20,40EUR | 0,90EUR | 4,62% |
WKN: 881319 / ISIN: NZFAPE0001S2
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 93,60 |
| Pinnacle Investment Management Group Ltd. | 6,15 |
| Hyperion Asset Management Ltd. | 6,05 |
| First Sentier Investors (Australia) IM Ltd. | 2,51 |
| First Sentier Invt. ICVC - Stewart Invt Asia Pac. Leaders Sust | 2,41 |
| New Zealand Superannuation Fund | 2,23 |
| Accident Compensation Corp. | 1,56 |
| Vanguard Total International Stock Index Fund | 1,37 |
| First Sentier Investors (Hong Kong) Ltd. | 1,16 |
| First Sentier Investors (Singapore) | 1,06 |
| Hyperion Australian Growth Companies Fund (Top 5 Holdings) | 1,04 |
| Smithson Investment Trust Plc | 1,03 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 5 081 | 6 897 | 7 375 | 6 564 | 7 141 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,25 | 0,28 | 0,22 | 0,24 | 0,25 |
Bilanz (in Mio. NZD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 519 | 920 | 888 | 774 | 705 |
| Summe Anlagevermögen | 916 | 1 155 | 1 219 | 1 430 | 1 577 |
| Summe Aktiva | 1 435 | 2 075 | 2 107 | 2 205 | 2 282 |
Bilanz (in Mio. NZD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 461 | 554 | 427 | 451 | 523 |
| Summe Eigenkapital | 974 | 1 521 | 1 680 | 1 753 | 1 759 |
| Summe Passiva | 1 435 | 2 075 | 2 107 | 2 205 | 2 282 |
Adresse
| 15 Maurice Paykel Place, 2013 Auckland | |
| Telefon | +64 (9) 574-0100 |
| Fax | +64 (9) 574-0158 |
| Internet | http://www.fphcare.com |
Management
|
Andrea Blackie
Deputy Chief Financial Officer |
|
Andrew Mark Cross
Independent Non-Executive Director |
|
Andrew Robert Donald Somervell
Vice President-Products & Technology |
|
Andy Niccol
Chief Operating Officer |
|
Brian Schultz
Vice President-Quality & Regulatory Affairs |
|
Dexter Cheung
Manager-Research & Development |
|
Graham Mclean
Independent Non-Executive Director |
|
Jonti Rhodes
VP-Supply Chain, Facilities & Sustainability |
|
Justin Callahan
Vice President-Sales & Marketing |
|
Karen Knotts
General Manager-Corporate Communications |
|
Lewis George Gradon
Chief Executive Officer, MD & Executive Director |
|
Lisa Margaret McIntyre
Independent Non-Executive Director |
|
Lyndal York
Chief Financial Officer |
|
Marcus Driller
Vice President-Corporate |
|
Michael Grenfell Daniell
Non-Executive Director |
|
Miriam Cather Simpson
Independent Non-Executive Director |
|
Neville J. Mitchell
Chairman |
|
Nicholas Fourie
VP-Information & Communication Technology |
|
Nicola Talbot
Vice President-Human Resources |
|
Philippa Mary Greenwood
Independent Non-Executive Director |
|
Raelene Leonard
Secretary & General Counsel |
|
Winston Fong
Vice President-Surgical Technologies |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
